Last checked at 4 Jul 2014 07:00
4 July 2014
Revolymer plc ("Revolymer" or "the Company")
Revolymer appoints Chief Executive Officer
Revolymer plc ("Revolymer"), the polymer technology company, is delighted to announce that it will appoint Dr Kevin Roger Kenneth Matthews as Chief Executive Officer with effect from 1 January 2015. Dr Matthews has over 20 years of experience in senior management roles in the chemical, technology and pharmaceutical sectors and will bring significant marketing, strategy and business management expertise, along with a broad technical understanding, to Revolymer's management team.
Dr Matthews will join Revolymer from Isogenica Ltd, a business providing drug discovery services to the pharmaceutical industry, where he has served as CEO since 2009. Prior to that, Dr Matthews led the chemical technology company Oxonica as its CEO for 8 years, during which time he completed its AIM listing in 2005 and secured numerous significant partnership deals and M&A transactions. He also is currently serving as non-executive director of the FTSE 250 specialty chemicals company, Elementis plc, a role he has held since 2005, where he has helped to oversee a significant and successful strategic repositioning of the business. Dr Matthews began his career holding a number of increasingly senior roles at ICI, Albright & Wilson and Rhodia. He is a graduate of the University of Oxford, where he was also awarded a DPhil in Organic Chemistry.
"I am excited to have this opportunity to lead Revolymer through the next phase of its development, continuing to identify and deliver on commercial opportunities where Revolymer's broad polymer technology expertise can provide real and sustainable value in solving customer and industry challenges. I look forward to working with the existing board, management and investors to build Revolymer into a global leader in its markets" said Dr Matthews.
Jack Keenan, Chairman of Revolymer plc, commented "We are very pleased to have appointed Dr Kevin Matthews to the role of CEO at Revolymer. He has the balance of relevant technical expertise and business management experience, including at listed companies, that the Board has been seeking. He has a proven track record of delivering commercial deals in businesses like Revolymer, and we look forward to near-term progress across Revolymer's business areas under his leadership."
Dr Matthews will formally join the board of Revolymer as Chief Executive Officer on 1 January 2015, at which point Robin Cridland will resume the role of Chief Financial Officer and Company Secretary.
Dr Kevin Roger Kenneth Matthews (aged 50) holds or has held the following directorships within the last 5 years:
Current | Previous |
Aspireto Limited | Oxonica Energy Limited |
Elementis PLC | Oxonica Healthcare Limited |
Cellectricon AB | Oxonica Inc. |
Isogenica CGL Limited | Oxonica Limited |
Isogenica IMG Limited | Oxonica Materials Inc. |
Isogenica Limited | Oxonica Materials Limited |
Oxonica Overseas Holdings Limited | |
Oxonica Singapore Pte Limited. |
Save as set out above, there is no information specified by paragraph (g) in Schedule Two to the AIM Rules that is required to be disclosed.
Ends
For further information please contact:
Revolymer plc | +44 (0) 1244 283 500 |
Rob Cridland
|
|
Panmure Gordon (UK) Limited | +44 (0) 20 7886 2500 |
Callum Stewart / Adam James (Corporate Finance) Charles Leigh-Pemberton (Corporate Broking) | |
Citigate Dewe Rogerson | +44 (0)20 7282 2867 |
David Dible / Malcolm Robertson
|
About Revolymer
Revolymer is a technology company that designs, develops and formulates novel polymers to improve the performance of existing consumer products within the FMCG and other industrial markets. Revolymer's strategy is to generate significant and growing revenue streams by licensing its unique and proprietary technologies to manufacturers and marketers within these global high value markets. Current applications for the Group's technologies are in the household products, personal care and coatings & adhesives markets (together "Consumer Specialties") and the medicated chewing gum and confectionery chewing gum (together "Gum") markets.
www.revolymer.com